SpringWorks Therapeutics Inc. will soon launch its first product after the US Food and Drug Administration approved the small molecule gamma secretase inhibitor Ogsiveo (nirogacestat) for adults with progressing desmoid tumors who require systemic treatment. As the first-ever drug approved to treat the rare tumors, Ogsiveo appears poised to enjoy a warm welcome from doctors and patients who have been searching for alternatives to often ineffective surgeries and off-label medicines.
Key Takeaways
-
The US FDA approved Ogsiveo on 27 November to treat adults with progressing desmoid tumors who require systemic treatment. The drug will be available within five to 10 days.
Stamford, CT-based SpringWorks, which plans to make the drug available in the US within five to 10 days of its...
